UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Pamrevlumab for the treatment of idiopathic pulmonary fibrosis

Expert opinion on investigational drugs, 2020-08, Vol.29 (8), p.771-777

2020

Volltextzugriff (PDF)

Feasibility and safety of oxygen saturation remote monitoring in COVID-19: A descriptive research

Clinical infection in practice, 2023-11, Vol.20, p.100240, Article 100240

2023

Volltextzugriff (PDF)

An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis

Expert opinion on biological therapy, 2023-12, Vol.23 (12), p.1239-1244

2023

Volltextzugriff (PDF)

Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis

Expert opinion on investigational drugs, 2024-02, Vol.33 (2), p.133-143

2024

Volltextzugriff (PDF)

BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)

Expert opinion on investigational drugs, 2023-01, Vol.32 (1), p.17-23

2023

Volltextzugriff (PDF)

Ventilatory Support in Patients with COVID-19

Coronavirus Disease - COVID-19, 2021-01, Vol.1318, p.469-483

2021

Volltextzugriff (PDF)

When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma

BMJ case reports, 2022-01, Vol.15 (1), p.e244503

2022

Volltextzugriff (PDF)

A randomized trial of pamrevlumab in patients with COVID ‐19 pneumonia

Respirology (Carlton, Vic.), 2023-10, Vol.28 (10), p.954-957

2023

Volltextzugriff (PDF)

Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue

Sarcoidosis, vasculitis, and diffuse lung diseases, 2020-01, Vol.37 (2), p.169-178

2020

Volltextzugriff (PDF)

Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey

The European respiratory journal, 2021-04, Vol.57 (4), p.2004219

2021

Volltextzugriff (PDF)

Solvent Casting and UV Photocuring for Easy and Safe Fabrication of Nanocomposite Film Dressings

Molecules (Basel, Switzerland), 2022-05, Vol.27 (9), p.2959

2022

Volltextzugriff (PDF)

Plastic breath: Quantification of microplastics and polymer additives in airborne particles

The Science of the total environment, 2024-07, Vol.932, p.173031-173031, Article 173031

2024

Volltextzugriff (PDF)

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Blood, 2021-11, Vol.138 (Supplement 1), p.4446-4446

2021

Volltextzugriff (PDF)

P451: GENE FUSIONS AND OTHER GENOMIC EVENTS UNDERLIE VENETOCLAX AND HYPOMETHYLATING AGENT RESISTANCE AND PROVIDE NEW TARGETS IN ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e25315b3-n/a

2023

Volltextzugriff (PDF)

Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing

Biomedicines, 2023-01, Vol.11 (2), p.359

2023

Volltextzugriff (PDF)

Correlation between antibiotic consumption and resistance of bloodstream bacteria in a University Hospital in North Eastern Italy, 2008–2014

Infection, 2017-08, Vol.45 (4), p.459-467

2017

Volltextzugriff (PDF)

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.1705-1707

2022

Volltextzugriff (PDF)

Abstract 1872: Pharmacological inhibition of WIP1 sensitizes AML cells to MDM2 inhibitors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1872-1872

2018

Volltextzugriff (PDF)

Abstract 2539: Antiapoptotic gene expression signature reveals a combined talk to prevent apoptosis: A model to choose the proper BH-3 mimetic drug

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2539-2539

2018

Volltextzugriff (PDF)

Abstract 2964: Pharmacological inhibition of WIP1 by GSK2830371 sensitizes AML cells to MDM2 inhibitor Nutlin-3a

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2964-2964

2019

Volltextzugriff (PDF)

A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination

Blood, 2017-12, Vol.130, p.4969-4969

2017

Volltextzugriff (PDF)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a

Biomedicines, 2021-04, Vol.9 (4), p.388

2021

Volltextzugriff (PDF)

Abstract 5279: Metabolic profiling defines a new characterization of acute myeloid leukemia and identifies NPM1 -mutated cases as a distinct subgroup

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.5279-5279

2019

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(34)

Publikationsform

Sprache

Englisch
(38)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Humans
(11)
Female
(5)
Pharmacology & Pharmacy
(5)
Aged
(4)
Idiopathic Pulmonary Fibrosis
(4)
Idiopathic Pulmonary Fibrosis - Drug Therapy
(4)
Medicine, Research & Experimental
(4)
Research & Experimental Medicine
(4)
Acute Myeloid Leukemia
(3)
Inflammation
(3)
Leukemia
(3)
Lung Fibrosis
(3)
Male
(3)
Middle Aged
(3)
Mutation
(3)
Precision Medicine
(3)
Respiratory System
(3)
Adolescent
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pamrevlumab for the treatment of idiopathic pulmonary fibrosis

Feasibility and safety of oxygen saturation remote monitoring in COVID-19: A descriptive research

An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis

Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis

BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)

Ventilatory Support in Patients with COVID-19

When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma

A randomized trial of pamrevlumab in patients with COVID ‐19 pneumonia

Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue

Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations

Solvent Casting and UV Photocuring for Easy and Safe Fabrication of Nanocomposite Film Dressings

Plastic breath: Quantification of microplastics and polymer additives in airborne particles

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

P451: GENE FUSIONS AND OTHER GENOMIC EVENTS UNDERLIE VENETOCLAX AND HYPOMETHYLATING AGENT RESISTANCE AND PROVIDE NEW TARGETS IN ACUTE MYELOID LEUKEMIA

Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing

Correlation between antibiotic consumption and resistance of bloodstream bacteria in a University Hospital in North Eastern Italy, 2008–2014

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE

Abstract 1872: Pharmacological inhibition of WIP1 sensitizes AML cells to MDM2 inhibitors

Abstract 2539: Antiapoptotic gene expression signature reveals a combined talk to prevent apoptosis: A model to choose the proper BH-3 mimetic drug

Abstract 2964: Pharmacological inhibition of WIP1 by GSK2830371 sensitizes AML cells to MDM2 inhibitor Nutlin-3a

A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a

Abstract 5279: Metabolic profiling defines a new characterization of acute myeloid leukemia and identifies NPM1 -mutated cases as a distinct subgroup

Suchergebnisse filtern